Dravet Syndrome Treatment Market Global Industry Demand, Recent Trends, Size and Share Estimation by 2026
View Report : https://www.transparencymarketresearch.com/dravet-syndrome-treatment-market.html
SCN1A is responsible for encoding the ?-subunit of the voltage-gated sodium channel NaV1.1. Recent studies, using genetically modified mouse models, have indicated that haploinsufficiency of NaV1.1 in GABAergic inhibitory interneurons in the forebrain may be involved in the fever sensitivity of seizures, seizure susceptibility, autistic traits, and premature death characteristics of Dravet syndrome. In recent years, human cellular models of Dravet syndrome have been recognized by the use of induced pluripotent stem cells (iPSCs) derived from patients. Functional susceptibilities in GABAergic neurons have been discovered by studying these human disease models.
Increasing R&D into new drug development for Dravet syndrome and approval for these drugs in key markets, such as, North America and Europe are anticipated to propel the development of the Dravet syndrome treatment market worldwide. For instance, in February 2018, Zogenix Inc. revealed U.S. Food and Drug Administration (FDA) approval of its Phase III drug ZX-008 for seizures associated with Dravet Syndrome.
Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=51576
In 2017, Epygenix Therapeutics, Inc., a biopharmaceutical company, received FDA orphan drug designation for its product, EPX-300, indicated for the treatment of the Dravet syndrome. In 2017, Ovid Therapeutics (the U.S.) got orphan drug designation from FDA for its product, TAK-935/OV935. Furthermore, collaborations among key market players for the development and manufacturing of drugs indicated for the treatment of Dravet syndrome are expected to drive the growth of the Dravet syndrome treatment market, globally. For instance, in 2017, Epygenix Therapeutics, Inc. and, Laurus Synthesis Inc. entered into a strategic collaboration for the development and manufacturing of EPX-100.
A recent U.S. epidemiology study concluded that Dravet syndrome incidence has increased to twice the previous year, affecting 1:15,700 infants, 80% of whom have an SCN1A mutation. Unfortunately, a large number of children do not get access to early diagnosis, which could have had a significant impact on long-term development and quality of life. The study concluded that genetic testing via an epilepsy panel should be considered in children with two or more prolonged seizures by the age of one year.
REQUEST FOR COVID19 IMPACT ANALYSIS - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=51576
The Dravet syndrome treatment market can be segmented based on treatment type, distribution channel, and geography. By treatment type, the market can be divided into anticonvulsant, benzodiazepines, vagal nerve stimulation, and others. In terms of distribution channel, the marekt can be categorized into hospital pharmacies, retail pharmacies, and online pharmacies.
On the basis of geography, the global Dravet syndrome treatment market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the leading share of the global Dravet syndrome treatment market in 2017, followed by Europe, due to growth initiatives and funding by various organizations to support the development of new treatment for Dravet syndrome. For instance, in 2017, Dravet Syndrome Foundation, a non-profit organization of the U.S., funded an amount of US$ 3,600,000 for the development of new treatment methods for the disorder.
Read our Case study at : https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up
The Dravet syndrome treatment market in Europe is likely to exhibit significant growth during the forecast period due to increasing research and development activities conducted by key market players in the region. For instance, a British biopharmaceutical company, GW Pharmaceuticals, developed Epidiolex (cannabidiol) ingredient derived from marijuana. The company submitted a new drug application (NDA) for Epidiolex to the U.S. FDA in December 2017. After approval, the drug is expected to hit the U.S. market by mid of 2018.
Key players operating in the Dravet syndrome treatment market include Epygenix Therapeutics, Inc., GW Pharmaceuticals Plc., Ovid Therapeutics, Takeda Pharmaceutical Company Ltd, OPKO Health Inc., Zogenix, Inc, Biocodex S.A., PTC Therapeutics, Inc., and Biscayne Neurotherapeutics, Inc. Key players in the market are focusing on obtaining approval for their new drugs from major regulatory bodies, such as, FDA and European Commission.
More Trending Reports by Transparency Market Research - 1. http://www.prnewswire.com/news-releases/animal-health-gains-prominence-as-role-shifts-from-pets-to-companions-contributing-to-growth-in-veterinary-radiography-system-market-notes-tmr-301022155.html
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dravet Syndrome Treatment Market Global Industry Demand, Recent Trends, Size and Share Estimation by 2026 here
News-ID: 2054183 • Views: 364
More Releases from Transparency Market Research
Lactose Market - Global Industry, Size, Share, Growth, Trends and Forecast 2029
With reference to the latest market forecast report published by Transparency Market Research, on the title 'Lactose Market: Global Industry Analysis and Opportunity Assessment 2019-2029', revenue generated from the global lactose market has been estimated to be valued around US$ 1,750.7 Mn in 2019, which is projected to increase at a CAGR of 4.4% to US$ 2,697.3 Mn in 2029, during the forecast period (2019-2029). 𝙍𝙚𝙦𝙪𝙚𝙨𝙩 𝘽𝙧𝙤𝙘𝙝𝙪𝙧𝙚 𝙤𝙛 𝙍𝙚𝙥𝙤𝙧𝙩 - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17099 Target
Aquaculture Market foreseen to grow exponentially over 2027
Transparency Market Research (TMR) delivers key insights on the global aquaculture market in its upcoming outlook titled, “Aquaculture Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2019-2027”. In terms of value, the global aquaculture market is projected to register a healthy CAGR of 2.3% during the forecast period due to various factors, regarding which TMR offers vital insights in detail. The farming and harvesting of aquatic species in aquaculture
Textured Butter Market foreseen to grow exponentially over 2029
The latest market report published by Transparency Market Research on the global textured butter market includes global industry analysis and opportunity assessment for 2019-2029. Revenue generated from the global textured butter market is estimated to reach ~ US$ 1 Bn in 2019, and is projected to increase at a CAGR of ~ 4%, to reach US$ 1.5 Bn in 2029. For More Information: https://www.transparencymarketresearch.com/textured-butter-market.html Textured Butter Widely Used as a Shortening in
Mezcal Market foreseen to grow exponentially over 2027
The global Mezcal market is set to see stellar growth in the period between 2019 and 2027. It is set to chart an impressive 13% CAGR in this period, creating sizeable growth opportunities for players to dabble with. It will also contribute to bringing the market worth up to USD 738 million by 2027. It is a steep rise from 2019 to 2027. The market is slightly fragmented and prominent players
More Releases for Dravet
Dravet Syndrome Therapeutics- Pipeline Analysis 2018 | Zogenix, Inc., Ovid Thera …
Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus. Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. Download the sample report @ https://www.pharmaproff.com/request-sample/1098 It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due
Dravet Syndrome Treatment Market Trends in 2019- What Industry Insiders Tell Us …
MarketResearchReports.Biz announces addition of new report "Dravet Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026" to its database. Dravet syndrome is a distressing infantile-onset epilepsy, which is sometimes accompanied by severe intellectual disabilities, autistic traits, hyperactive behavior, and ataxia. Discovery of SCN1A mutation in 2001 as a primary cause of this syndrome has accelerated the knowledge of the pathophysiological processes behind Dravet syndrome.
Dravet Syndrome Treatment Market - Substantial Rise in Industrial Sectors to Off …
The newly released research at Up Market Research titled “2019 - 2025 Global Dravet Syndrome Treatment Market Report” provides data, information, brief analysis, company profiles, statistics for past years and forecasts for next few years. This report presents a comprehensive overview, market shares, and growth opportunities of Dravet Syndrome Treatment Market by product type, application, key manufacturers and key regions. Request Sample Copy Of this Report @ https://www.upmarketresearch.com/home/requested_sample/77681 Dravet Syndrome Treatment
2023 Dravet Syndrome Market Players Adopting to Ensure Sustainability | Biocodex …
Market Research Future recently presented Global Dravet Syndrome Market study with detailed review, portraying about the Product/Industry Scope and expounds market outlook and status to 2023. Dravet Syndrome Market - Highlights Dravet Syndrome is a severe form of the epileptic disorder that initiates in the first year of an otherwise healthy infant. Around 85% of children with Dravet syndrome develop myoclonic seizures between 1-5 years. Many factors such as the development of new
Global Dravet Syndrome Treatment Market Status, Share, Significant Trends, Drive …
An up-to-date research report has been disclosed by Market Research Hub highlighting the title “Global Dravet Syndrome Treatment Market Insights, Forecast to 2025” which provides an outlook for current market value as well as the expected growth of Dravet Syndrome Treatment Market during 2018-2025. The report studies the casing heads market worldwide, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, size, growth, revenue, consumption, import
Dravet Syndrome Treatment Market - Global Industry Insights, 2026
Dravet syndrome (DS), also known as epilepsy with polymorphic seizures and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic dysfunction of the brain (epileptic encephalopathy). It usually begins in first year of life and remains throughout lifetime. Children suffering from dravet syndrome suffer from different type of seizures namely, myoclonic seizures, tonic-clonic seizures, absence seizures, atypical absence seizures, atonic seizures, focal aware or impaired awareness seizures (previously